Samira M Garonzik - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Filters

Samira M Garonzik

Showing results (1-10 of 10) with videos related to

Pageof 1

Sort By:

Drugs in R&D|August 7, 2021

Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic ImpairmentCharles E Frost, Van Ly, Samira M Garonzik

Plos One|June 11, 2016

Defining the Active Fraction of Daptomycin against Methicillin-Resistant Staphylococcus aureus (MRSA) Using a Pharmacokinetic and Pharmacodynamic ApproachSamira M Garonzik, Justin R Lenhard, Alan Forrest, et al.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2017

Reply to Corona and CattaneoRoger L Nation, Samira M Garonzik, Visanu Thamlikitkul, et al.

Antimicrobial Agents and Chemotherapy|September 13, 2017

Pharmacokinetic/Toxicodynamic Analysis of Colistin-Associated Acute Kidney Injury in Critically Ill PatientsAlan Forrest, Samira M Garonzik, Visanu Thamlikitkul, et al.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 25, 2016

Dosing guidance for intravenous colistin in critically-ill patientsRoger L Nation, Samira M Garonzik, Visanu Thamlikitkul, et al.

Clinical Pharmacokinetics|October 10, 2012

Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal womenJulie B Dumond, Melanie R Nicol, Racheal N Kendrick, et al.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 27, 2015

Updated US and European Dose Recommendations for Intravenous Colistin: How Do They Perform?Roger L Nation, Samira M Garonzik, Jian Li, et al.

Arteriosclerosis, Thrombosis, and Vascular Biology|September 10, 2020

Antithrombotic Effects of Combined PAR (Protease-Activated Receptor)-4 Antagonism and Factor Xa InhibitionMohammed N Meah, Jennifer Raftis, Simon J Wilson, et al.

Bioanalysis|November 19, 2016

UHPLC-MS/MS bioanalysis of urinary DHEA, cortisone and their hydroxylated metabolites as potential biomarkers for CYP3A-mediated drug-drug interactionsNaiyu Zheng, Lisa J Christopher, Xuewen Ma, et al.

The Journal of Antimicrobial Chemotherapy|March 24, 2017

Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activityJustin R Lenhard, Visanu Thamlikitkul, Fernanda P Silveira, et al.

Pageof 1

Search research articles

Showing results (1-10 of 10) with videos related to

Sort By:

Pageof 1

Drugs in R&D|August 7, 2021

Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic ImpairmentCharles E Frost, Van Ly, Samira M Garonzik

Plos One|June 11, 2016

Defining the Active Fraction of Daptomycin against Methicillin-Resistant Staphylococcus aureus (MRSA) Using a Pharmacokinetic and Pharmacodynamic ApproachSamira M Garonzik, Justin R Lenhard, Alan Forrest, et al.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2017

Reply to Corona and CattaneoRoger L Nation, Samira M Garonzik, Visanu Thamlikitkul, et al.

Antimicrobial Agents and Chemotherapy|September 13, 2017

Pharmacokinetic/Toxicodynamic Analysis of Colistin-Associated Acute Kidney Injury in Critically Ill PatientsAlan Forrest, Samira M Garonzik, Visanu Thamlikitkul, et al.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 25, 2016

Dosing guidance for intravenous colistin in critically-ill patientsRoger L Nation, Samira M Garonzik, Visanu Thamlikitkul, et al.

Clinical Pharmacokinetics|October 10, 2012

Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal womenJulie B Dumond, Melanie R Nicol, Racheal N Kendrick, et al.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 27, 2015

Updated US and European Dose Recommendations for Intravenous Colistin: How Do They Perform?Roger L Nation, Samira M Garonzik, Jian Li, et al.

Arteriosclerosis, Thrombosis, and Vascular Biology|September 10, 2020

Antithrombotic Effects of Combined PAR (Protease-Activated Receptor)-4 Antagonism and Factor Xa InhibitionMohammed N Meah, Jennifer Raftis, Simon J Wilson, et al.

Bioanalysis|November 19, 2016

UHPLC-MS/MS bioanalysis of urinary DHEA, cortisone and their hydroxylated metabolites as potential biomarkers for CYP3A-mediated drug-drug interactionsNaiyu Zheng, Lisa J Christopher, Xuewen Ma, et al.

The Journal of Antimicrobial Chemotherapy|March 24, 2017

Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activityJustin R Lenhard, Visanu Thamlikitkul, Fernanda P Silveira, et al.

Pageof 1